O

    Olema Pharmaceuticals Inc (OLMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.43
    +0.16 (+1.56%)

    Market Cap: $898.60M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(10/24)
    Avg Surprise
    -21.96%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.67
    Range$-0.73 - $-0.62
    5 analysts
    EPS Revisions
    5
    0
    7d
    5
    3
    30d
    EPS Estimate Drift
    90d ago$-0.57+14.5%
    60d ago$-0.57+14.7%
    30d ago$-0.58+13.0%
    7d ago$-0.58+13.0%
    Current$-0.67
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.65
    Range$-0.92 - $-0.54
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.65---
    Sep 26EST
    		-$-0.67---
    Jun 26
    		$-0.61$-0.53-15.09%Miss-19.6%
    Mar 26
    		$-0.52$-0.54+3.70%Beat-44.4%
    Dec 25
    		$-0.50$-0.52+3.28%Beat+1.1%
    Sep 25
    		$-0.49$-0.45-8.89%Miss+18.3%
    Jun 25
    		$-0.51$-0.44-15.91%Miss+5.6%
    Mar 25
    		$-0.36$-0.46+21.74%Beat+35.7%
    Dec 24
    		$-0.51$0.17-394.46%Miss-4.1%
    Sep 24
    		$-0.60$-0.57-5.26%Miss-25.0%
    Jun 24
    		$-0.54$-0.54+0.00%Beat-10.2%
    Mar 24
    		$-0.56$-0.55-1.82%Miss+20.0%
    Dec 23
    		$-0.49$-0.48-2.08%Miss+24.6%
    Sep 23
    		$-0.48$-0.51+5.88%Beat+15.8%
    Jun 23
    		$-0.49$-0.71+30.99%Beat+40.2%
    Mar 23
    		$-0.70$-0.69-1.45%Miss-20.7%
    Dec 22
    		$-0.65$-0.65+0.00%Beat-20.4%
    Sep 22
    		$-0.57$-0.78+26.92%Beat-26.7%
    Jun 22
    		$-0.82$-0.66-24.24%Miss-95.2%
    Mar 22
    		$-0.58$-0.60+3.33%Beat-48.7%
    Dec 21
    		$-0.54$-0.49-10.20%Miss-8.0%
    Sep 21
    		$-0.45$-0.43-4.65%Miss-1400.0%
    Jun 21
    		$-0.42$-0.38-10.53%Miss-
    Mar 21
    		$-0.39$-0.27-44.44%Miss-
    Dec 20
    		$-0.50$-0.18-177.78%Miss-
    Sep 20
    		$-0.03N/A+94.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-4.91EV/EBITDA-3.33x
    Price/FCF-6.61xFCF Yield-15.12%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.70%ROIC-40.36%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio8.86xQuick Ratio8.86x
    Trading Statistics
    Beta2.01Avg Volume984.59K
    52-Week High$36.2652-Week Low$5.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.72
    SMA 20$10.96
    SMA 50$11.40
    SMA 200$17.69
    EMA 10$10.68
    EMA 20$10.89
    EMA 50$11.43
    EMA 200$13.58

    MACD

    Line: -0.26Signal: -0.23Hist: -0.03

    ADX

    ADX: 24.3+DI: 15.1-DI: 26.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down44.0
    PSAR$11.83

    Bollinger Bands

    Upper Band$12.10
    Lower Band$9.82
    %B Position2078%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    42.4

    Momentum Oscillators

    Stoch %K35.0
    Stoch %D40.7
    Williams %R-73.0
    ROC (10d)-3.2%
    Momentum-0.34
    CCI (20d)-88.0
    MFI (14d)45.6

    Volatility Measures

    ATR (14d)$0.58(5.6%)
    StdDev (20d)0.57
    Hist Vol63.1%(High)

    Volume Flow

    VWAP$10.35
    OBV62.3M
    AD Line-49.3M
    CMF (20d)0.091

    Volume Metrics

    Avg Vol (20d)995.6K
    Vol Ratio0.9x
    VWMA (20d)$10.91

    Pivot Points

    R3$11.21
    R2$10.99
    R1$10.63
    Pivot Point$10.41
    S1$10.05
    S2$9.83
    S3$9.47

    Advanced Oscillators

    TSI-12.18
    Ultimate Osc48.8
    KST-87.20

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$364,000$0$0$0$1.88M$0
    Cost of Revenue$0$0$187,000$0$0$0$182,000$0$0$0$88,000$0
    Gross Profit$0$0$-187,000$0$0$0$182,000$0$0$0$1.80M$0
    Operating Expenses$67.18M$57.99M$50.08M$45.88M$47.86M$34.87M$36.77M$37.62M$33.53M$34.34M$30.42M$23.34M
    R&D$57.78M$49.23M$43.22M$39.95M$43.90M$30.62M$32.30M$33.23M$29.11M$29.88M$25.87M$19.45M
    SG&A$9.39M$8.75M$6.86M$5.93M$3.96M$4.25M$4.47M$4.39M$4.42M$4.46M$4.54M$3.89M
    Operating Income$-67,179,000$-57,986,000$-50,084,000$-45,877,000$-47,864,000$-34,873,000$-36,768,000$-37,621,000$-33,530,000$-34,339,000$-30,416,000$-23,342,000
    Interest Income$4.51M$4.78M$4.01M$3.65M$4.04M$4.52M$3.29M$2.93M$3.11M$3.35M$3.55M$1.92M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-63,200,000$-53,089,000$-46,061,000$-42,217,000$-43,784,000$-30,389,000$-33,567,000$-34,555,000$-30,382,000$-30,970,000$-26,772,000$-21,502,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-63,200,000$-53,089,000$-46,061,000$-42,217,000$-43,784,000$-30,389,000$-33,567,000$-34,555,000$-30,382,000$-30,970,000$-26,772,000$-21,502,000
    EBITDA$-67,605,000$-57,746,000$-49,884,000$-45,822,000$-47,694,000$-34,785,000$-36,745,000$-37,388,000$-33,396,000$-34,234,000$-30,235,000$-23,331,000
    EBIT$-67,707,000$-57,865,000$-50,071,000$-45,865,000$-47,826,000$-34,913,000$-36,861,000$-37,483,000$-33,490,000$-34,322,000$-30,323,000$-23,421,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OLMA

    News

    Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages

    Olema Pharmaceuticals (NASDAQ:OLMA) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average 12-month price target of $42.40 despite recent target reductions from several firms. The stock has experienced a sharp decline, opening at $10.43, and the company reported a quarterly EPS loss of $0.61, missing analyst expectations. Institutional investors hold a significant 91.78% of the shares, while an insider recently sold 12,500 shares.

    MarketBeat•8/25/26•
    Neutral

    J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46

    J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and maintained a target price of $46. This continued positive outlook from the financial institution suggests confidence in the company's future performance. The maintained target price indicates that J.P. Morgan analysts believe the stock has significant upside potential from its current trading levels.

    Moomoo•8/18/26•
    Neutral

    J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46

    J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and set a price target of $46. This indicates a positive outlook from the firm regarding the company's future performance.

    Moomoo•8/13/26•
    Bullish

    Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com

    This article from Investing.com reports on an SEC Form 8-K filing by Olema Pharmaceuticals Inc. for August 13th. The content is brief, primarily serving as an announcement of the filing rather than providing detailed analysis. The article includes standard financial market data and popular news links, but the core information is the Form 8-K disclosure.

    Investing.com Nigeria•8/13/26•
    Neutral

    Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com

    This article announces the filing of a Form 8K by Olema Pharmaceuticals Inc. on August 13. It includes the stock symbol OLMA and indicates a slight negative change in its price. The content provides a general news format from Investing.com with market data and related articles.

    Investing.com Canada•8/13/26•
    Neutral

    Frequently Asked Questions About OLMA

    Does OLMA pay dividends?
    Olema Pharmaceuticals Inc (OLMA) does not currently pay a regular dividend.
    What is OLMA's market cap?
    Olema Pharmaceuticals Inc (OLMA) has a market capitalization of $898.60M with a current stock price of $10.43.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In